businesspress24.com - Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference
 

Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference

ID: 1411749

(firmenpresse) - THE WOODLANDS, TX -- (Marketwired) -- 01/28/16 -- (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 11:00 a.m. EST in the Louis XVI Room. The conference will be held at the Waldorf Astoria Hotel in New York, NY.

A live webcast of the company presentation can be accessed , or via the Investor Relations section of the Company''s website at . An archive of the webcast will be available on the Company''s website until May 8, 2016.

Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa''s proprietary T-cell technology. The Company''s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient''s peripheral blood and reintroduced into the same patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.

For more information, visit the Opexa Therapeutics website at or follow company news on via (at)OpexaCEO.



Company Contact:
Karthik Radhakrishnan
Opexa Therapeutics, Inc.
Chief Financial Officer
281-775-0600



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Spotlight Innovation Inc. Engages Renowned Oncologist Prof. David Khayat as Principal Investigator for Its European Phase I Clinical Study for Crotoxin
Biostem Technologies, Inc. (OTC: BSEM) Announces Commencement of International Operations in Guadalajara, Mexico
Bereitgestellt von Benutzer: Marketwired
Datum: 28.01.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 1411749
Anzahl Zeichen: 2410

contact information:
Contact person:
Town:

THE WOODLANDS, TX


Phone:

Kategorie:

Alternative


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 207 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von

Opexa Therapeutics, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Opexa Therapeutics, Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 67


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.